Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Long-Term Efficacy and Clinical Remission After Benralizumab Treatment in Patients with Severe Eosinophilic Asthma: A Retrospective Study
Takanori Numata, Jun Araya, Keitaro Okuda, et al.
Journal of Asthma and Allergy (2022) Vol. Volume 15, pp. 1731-1741
Open Access | Times Cited: 26

Showing 1-25 of 26 citing articles:

Exploring Definitions and Predictors of Severe Asthma Clinical Remission after Biologic Treatment in Adults
Luis Pérez de Llano, Ghislaine Scélo, Trung N. Tran, et al.
American Journal of Respiratory and Critical Care Medicine (2024) Vol. 210, Iss. 7, pp. 869-880
Open Access | Times Cited: 28
Severe Asthma Remissions Induced by Biologics Targeting IL5/IL5r: Results from a Multicenter Real-Life Study
Angelantonio Maglio, Carolina Vitale, Corrado Pelaia, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2455-2455
Open Access | Times Cited: 34
Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients
Dennis Thomas, Vanessa M. McDonald, Sean Stevens, et al.
Allergy (2023) Vol. 79, Iss. 2, pp. 384-392
Open Access | Times Cited: 30
Benralizumab for eosinophilic granulomatosis with polyangiitis
Adrien Cottu, Matthieu Groh, Charlene Desaintjean, et al.
Annals of the Rheumatic Diseases (2023) Vol. 82, Iss. 12, pp. 1580-1586
Closed Access | Times Cited: 24
Comparison of clinical remission criteria for severe asthma patients receiving biologic therapy
Anna Breslavsky, Ahsen Al Qaied, Philip Tsenter, et al.
Respiratory Medicine (2024) Vol. 222, pp. 107528-107528
Closed Access | Times Cited: 10
Unlocking the Long-Term Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A Three-Year Real-Life Study
Laura Pini, Diego Bagnasco, Bianca Beghè, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 10, pp. 3013-3013
Open Access | Times Cited: 9
Real-world clinical remission of severe asthma with benralizumab in Spanish adults with severe asthma
Eva Martínez‐Moragón, Eusebi Chiner, Alexandra Suliana Mogrovejo, et al.
Journal of Asthma (2024) Vol. 61, Iss. 10, pp. 1190-1204
Closed Access | Times Cited: 8
Severe asthma clinical remission after biologic treatment with anti-IL4/IL13: A real-life experience
Andrea Portacci, Ilaria Iorillo, Vitaliano Nicola Quaranta, et al.
Respiratory Medicine (2023) Vol. 217, pp. 107348-107348
Closed Access | Times Cited: 21
Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study
Alessandra Vultaggio, Maria Aliani, Elena Altieri, et al.
Respiratory Research (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 20
Clinical Asthma Remission Obtained with Biologics in Real Life: Patients’ Prevalence and Characteristics
Bruno Sposato, Francesco Bianchi, Alberto Rícci, et al.
Journal of Personalized Medicine (2023) Vol. 13, Iss. 6, pp. 1020-1020
Open Access | Times Cited: 17
Effect of Azithromycin on Asthma Remission in Adults With Persistent Uncontrolled Asthma
Dennis Thomas, Vanessa M. McDonald, Sean Stevens, et al.
CHEST Journal (2024) Vol. 166, Iss. 2, pp. 262-270
Open Access | Times Cited: 7
Real-World Safety and Effectiveness of Benralizumab in Japanese Patients with Severe Asthma: A Multicenter Prospective Observational Study
Masao Yamaguchi, Yoshihiro Nishimura, Y Takumi, et al.
Journal of Asthma and Allergy (2024) Vol. Volume 17, pp. 45-60
Open Access | Times Cited: 6
Clinical remission attainment, definitions, and correlates among patients with severe asthma treated with biologics: a systematic review and meta-analysis
Amy Shackleford, Liam G. Heaney, Charlene Redmond, et al.
The Lancet Respiratory Medicine (2024)
Open Access | Times Cited: 6
OPTIMAL: Titration of anti-IL5 biologics in severe asthma - An open label randomised controlled trial
Marianne Baastrup Soendergaard, Anne‐Sofie Bjerrum, Linda Rasmussen, et al.
European Respiratory Journal (2024) Vol. 64, Iss. 2, pp. 2400404-2400404
Open Access | Times Cited: 5
Clinical Remission of Mild-to-Moderate Asthma: Rates, Contributing Factors, and Stability
Mana Ishizuka, Naoya Sugimoto, Konomi Kobayashi, et al.
Journal of Allergy and Clinical Immunology Global (2025), pp. 100431-100431
Open Access
Remission in Type 2 Inflammatory Diseases: Current Evidence, Unmet Needs, and Suggestions for Defining Remission in Chronic Rhinosinusitis with Nasal Polyps
Marco Caminati, Eugenio De Corso, Giancarlo Ottaviano, et al.
Current Allergy and Asthma Reports (2023) Vol. 24, Iss. 1, pp. 11-23
Open Access | Times Cited: 12
The true extent of eosinophil involvement in disease is unrecognized: the secret life of dead eosinophils
Kristin M. Leiferman, Gerald J. Gleich
Journal of Leukocyte Biology (2024)
Closed Access | Times Cited: 4
Identifying Super-Responders: a Review of the Road to Asthma Remission
Samuel Mailhot-Larouche, C.A. Celis-Preciado, Liam G. Heaney, et al.
Annals of Allergy Asthma & Immunology (2024)
Open Access | Times Cited: 4
Unlocking the Long-Term Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A Three-Year Real-Life Study
Laura Pini, Diego Bagnasco, Bianca Beghè, et al.
(2024)
Open Access | Times Cited: 3
Defining response to therapy with biologics in severe asthma: from global evaluation to super response and remission
Andriana Ι. Papaioannou, Evangelia Fouka, Κonstantinos Bartziokas, et al.
Expert Review of Respiratory Medicine (2023) Vol. 17, Iss. 6, pp. 481-493
Closed Access | Times Cited: 8
Clinical remission maintained and improved over time in patients with severe asthma treated with omalizumab
Aykut Çilli, Fatih Üzer, Gamze Ozbey
Journal of Asthma (2024) Vol. 61, Iss. 11, pp. 1469-1476
Closed Access | Times Cited: 2
Are we overlooking the lung function in the definition of severe asthma remission?
Santi Nolasco, Raffaele Campisi, Nunzio Crimi, et al.
Pulmonology (2023) Vol. 30, Iss. 4, pp. 324-326
Open Access | Times Cited: 6
Variables predicting clinical remission among adults with severe asthma treated with biologic agents
Selma Yeşilkaya, Kurtuluş Aksu, Gürgün Tuğçe Vural Solak, et al.
European Annals of Allergy and Clinical Immunology (2023) Vol. 56, Iss. 05, pp. 219-219
Open Access | Times Cited: 5
Effectiveness of benralizumab in the Tokyo Asthma Study (TOAST): A real-world prospective interventional trial
Katsunori Masaki, Maho Suzukawa, Hitoshi Sasano, et al.
Allergology International (2024)
Open Access | Times Cited: 1
Clinical Remission among Severe Asthmatics on Monoclonal Antibody Therapy: Real-World Outcomes at Two Years
Fred Fyles, R C Burton, Amy Nuttall, et al.
ERJ Open Research (2024) Vol. 10, Iss. 6, pp. 00261-2024
Open Access
Page 1 - Next Page

Scroll to top